SLC5A2 and chronic kidney disease: Sodium-glucose cotransporter-2(SGLT2) inhibitors and Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are regarded as excellent second-line agents for people with CKD (9, 22, 36, 37).